Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.
You may also be interested in...
Genitope Pulls Plug On Cancer Vaccine
FDA wants another Phase III trial with non-Hodgkins lymphoma drug.
Favrille’s Acquisition Of Diversa CD20 Antibodies Bolsters Lead Lymphoma Program
Another firm developing a therapeutic vaccine for lymphoma, Biovest, says it hopes to launch its BiovaxID product in mid-2009.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.